Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of paricalcitol capsules in pediatric Stage 5 CKD on dialysis
2013-002610-13Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of paricalcitol in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by AbbVie Inc. Started Aug 2013; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2013-002610-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002610-13.